A randomised controlled trial of intramuscular vs. intravenous antivenom for latrodectism--the RAVE study
Authors:
- G.K. IsbisterGIG.K. Isbister
- S.G.A. BrownSBS.G.A. Brown
- M. MillerMMM. Miller
- A. TankelATA. Tankel
- E. MacdonaldEME. Macdonald
- B. StokesBSB. Stokes
- R. EllisRER. Ellis
- Y. NagreeYNY. Nagree
- G.J. WilkesGWG.J. Wilkes
- R. JamesRJR. James
- A. ShortASA. Short
- A. HoldgateAHA. Holdgate
Open Access
- 4 March 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in QJM: An International Journal of Medicine
- Vol. 101 (7) , 557-565
Abstract
Background: Widow spider-bite causes latrodectism and is associated with significant morbidity worldwide. Antivenom is given by both the intravenous (IV) and intramuscular (IM) routes and it is unclear which is more effective. Aim: To compare the effectiveness of IV vs. IM redback spider antivenom. Design: Randomized controlled trial. Methods: Patients with latrodectism were given either IV or IM antivenom according to a randomized double-dummy, double-blind protocol. The first antivenom treatment was followed by another identical treatment after two hours if required. The primary outcome was a clinically significant reduction in pain two hours after the last treatment. A fully Bayesian analysis was used to estimate the probability of the desired treatment effect, predetermined as an absolute difference of 20%. Results: We randomly allocated 126 patients to receive antivenom IV (64) and IM (62). After antivenom treatment pain improved in 40/64(62%) in the IV group vs. 33/62(53%) in the IM group (+9%; 95% Credible Interval [CrI]: –8% to +26%). The probability of a difference greater than zero (IV superior) was 85% but the probability of a difference >20% was only 10%. In 55 patients with systemic effects, these improved in 58% after IV antivenom vs. 65% after IM antivenom (−8%; 95% CrI: –32% to +17%). Twenty-four hours after antivenom pain had improved in 84% in the IV group vs. 71% in the IM group (+13%; 95% CrI: –2% to +27%). A meta-analysis including data from a previous trial found no difference in the primary outcome between IV and IM administration. Discussion: The difference between IV and IM routes of administration of widow spider antivenom is, at best, small and does not justify routinely choosing one route over the other. Furthermore, antivenom may provide no benefit over placebo.Keywords
This publication has 20 references indexed in Scilit:
- A double‐blind, randomized trial of intravenous versus intramuscular antivenom for Red‐back spider envenomingEmergency Medicine Australasia, 2005
- Pharmacokinetic studies of scorpion venom before and after antivenom immunotherapyToxicon, 2005
- Clinical consequences of spider bites: recent advances in our understandingToxicon, 2004
- Latrodectism: a prospective cohort study of bites by formally identified redback spidersMedical Journal of Australia, 2003
- Latrodectism: a prospective cohort study of bites by formally identified redback spidersMedical Journal of Australia, 2003
- Antivenom Treatment in ArachnidismJournal of Toxicology: Clinical Toxicology, 2003
- Failure of intramuscular antivenom in Red‐back spider envenomingEmergency Medicine, 2002
- Data Collection in Clinical Toxinology: Debunking Myths and Developing Diagnostic Algorithms*Journal of Toxicology: Clinical Toxicology, 2002
- Evaluation of antivenom therapy in children severely envenomed by Androctonus australis garzonii (Aag) and Buthus occitanus tunetanus (Bot) scorpionsToxicon, 1999
- Clinical presentation and treatment of black widow spider envenomation: A review of 163 casesAnnals of Emergency Medicine, 1992